Compare Cytokinetics Inc (CYTK) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Under Armour Inc Class A — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while Under Armour Inc Class A trades at $4.88 (market cap $2.07B). The key difference: Cytokinetics Inc is far larger — about 4.2× Under Armour Inc Class A's market cap, and Under Armour Inc Class A is more actively traded (12,050,442 versus 2,594,626). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Under Armour Inc Class A for 99 Days on average.
| CYTK | UAA | |
|---|---|---|
Market Cap | $8.62B | $2.07B |
Volume | 2,594,626 | 12,050,442 |
Sector | Health | Consumer Cyclical |
52-Week High | $87.26 | $8.14 |
52-Week Low | $54.76 | $4.17 |
Typical Hold Time | 19 Days | 99 Days |
Enterprise Value | $8.72B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
Under Armour (UAA) trades at $4.82, down 1.23% on the day, with a mixed technical picture showing a bullish overall signal but a neutral RSI. The company reported a net loss of $201.27 million in 2025, with revenue declining to $5.16 billion, though recent quarters have shown some earnings beats. Analyst consensus is a $5.79 price target, but the stock faces headwinds from weak consumer demand and negative cash flow trends.
The outlook is cautious; while cost discipline supports margins, persistent revenue weakness and negative profitability pose significant risks. The stock's low P/S ratio of 0.42 may attract value investors, but sustained operational improvements are needed for a durable recovery amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
